Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
& Bader, G
The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions
RESTRICTIONS OF USE DURING PREGNANCY AND BREASTFEEDING Do not take during pregnancy or breastfeeding
prescription, accepts payment only in cryptocurrency, or labels its vials "research chemical, not for human use." Prices that sit far below every licensed pharmacy, the absence of a reachable pharmacist, and no requirement for a clinical review are each signals that the product may be counterfeit, mislabeled, or non-sterile
In a 48-week phase II clinical trial conducted on patients with type 2 diabetes and obesity, treatment with a dose of 10 mg/kg of bimagrumab resulted in a significant reduction in fat mass by 20.5% (compared to 0.5% in the placebo group), while lean body mass increased by 3.6% (as opposed to a decrease of 0.8% in the placebo group), leading to an overall body weight reduction of -6.5%, which was substantially better than the -0.8% observed in the placebo group
